» Articles » PMID: 30863084

Up-regulation of CKAP2L Expression Promotes Lung Adenocarcinoma Invasion and is Associated with Poor Prognosis

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2019 Mar 14
PMID 30863084
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: The purpose of this study is to consider the function of cytoskeleton-associated protein 2-like (CKAP2L) in lung adenocarcinoma (LAD) development and its prognostic value.

Methods: The mRNA expression of CKAP2L and its correlation with clinical factors in LAD patients were analyzed from the data taken from The Cancer Genome Atlas and The First Affiliated Hospital of Kunming Medical University. We constructed H460 and A549 cell lines with silenced CKAP2L using RNA interference. Cell counting kit-8 assay and colony formation assays were carried out to determine the function of CKAP2L in H460 and A549 cell proliferation. Transwell and wound healing assays were applied to determine the effect of CKAP2L on H460 and A549 cell invasion and migration. The influences of CKAP2L on mitogen-activated protein kinase signaling pathway-related proteins were tested by Western blotting.

Results: CKAP2L expression is enhanced in LAD tissues and is predictive of poor prognosis in LAD patients. High expression of CKAP2L is associated with stage (<0.001), lymph node status (=0.002), and metastasis (=0.025). Depletion of CKAP2L dramatically suppressed the proliferation, migration, and invasion of H460 and A549 cells. Moreover, the ratio of p-MEK/ MEK and p-ERK/ERK reduced obviously in A549 cells after depleting CKAP2L.

Conclusion: Our findings implied that CKAP2L might be a promoter of LAD and could serve as a predictor for LAD patients.

Citing Articles

Human CKAP2L shows a cell cycle-dependent expression pattern and exhibits microtubule-stabilizing properties.

Kwon H, Joh J, Hong K FEBS Open Bio. 2024; 14(9):1526-1539.

PMID: 39073037 PMC: 11492392. DOI: 10.1002/2211-5463.13864.


Identification of HPV oncogene and host cell differentiation associated cellular heterogeneity in cervical cancer via single-cell transcriptomic analysis.

Li Y, Wang C, Ma A, Rani A, Luo M, Li J bioRxiv. 2023; .

PMID: 37645794 PMC: 10462038. DOI: 10.1101/2023.08.10.552878.


Prognostic significance of CKAP2L expression in patients with clear cell renal cell carcinoma.

Liu Z, Zhang J, Shen D, Hu X, Ke Z, Lister I Front Genet. 2023; 13:873884.

PMID: 36699449 PMC: 9870291. DOI: 10.3389/fgene.2022.873884.


CKAP2L Promotes Esophageal Squamous Cell Carcinoma Progression and Drug-Resistance by Modulating Cell Cycle.

Chen W, Wang Y, Wang L, Zhao H, Li X J Oncol. 2022; 2022:2378253.

PMID: 36090903 PMC: 9462994. DOI: 10.1155/2022/2378253.


Identification of potential circular RNA biomarkers in lung adenocarcinoma: A bioinformatics analysis and retrospective clinical study.

Zhu Y, Cao F, Liu F, Liu S, Meng L, Gu L Oncol Lett. 2022; 23(5):144.

PMID: 35340554 PMC: 8931838. DOI: 10.3892/ol.2022.13264.


References
1.
Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

2.
Lai C, Lee J, Ho C, Liu C, Wang J, Wang Y . Rosmanol potently inhibits lipopolysaccharide-induced iNOS and COX-2 expression through downregulating MAPK, NF-kappaB, STAT3 and C/EBP signaling pathways. J Agric Food Chem. 2009; 57(22):10990-8. DOI: 10.1021/jf9025713. View

3.
Ahmed A, Lu Z, Jennings N, Etemadmoghadam D, Capalbo L, Jacamo R . SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell. 2010; 18(2):109-21. PMC: 3954541. DOI: 10.1016/j.ccr.2010.06.018. View

4.
Jakobsen L, Vanselow K, Skogs M, Toyoda Y, Lundberg E, Poser I . Novel asymmetrically localizing components of human centrosomes identified by complementary proteomics methods. EMBO J. 2011; 30(8):1520-35. PMC: 3102290. DOI: 10.1038/emboj.2011.63. View

5.
Reck M, Heigener D, Mok T, Soria J, Rabe K . Management of non-small-cell lung cancer: recent developments. Lancet. 2013; 382(9893):709-19. DOI: 10.1016/S0140-6736(13)61502-0. View